686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY
Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Yun‐Jung Choi(CymaBay Therapeutics (United States)), Marlyn J. Mayo(The University of Texas Southwestern Medical Center), Mitchell L. Shiffman(Bon Secours Health System), Christoph Berg, Klara Dickinson, John M. Vierling, Sandrin C. Bergheanu, Aliya Gulamhusein, Aparna Goel(Stanford University), Charles Landis(Albert Einstein College of Medicine), Gideon M. Hirschfield(University of Birmingham), Christopher L. Bowlus(University of Padua), Richard Aspinall(Queen Alexandra Hospital), Marcus‐Alexander Wörns, Adam Peyton, Tarek Hassanein, Charles A. McWherter(CymaBay Therapeutics (United States)), Stuart C. Gordon(Henry Ford Health System), Alexandra Steinberg(CymaBay Therapeutics (United States)), Pol Boudes(CymaBay Therapeutics (United States)), Paul J. Thuluvath(Inova Fairfax Hospital), Cynthia Levy(University of Miami), Palak Trivedi, Lynsey Corless(University of Hull), Peter Buggisch(Universität Hamburg), Mark G. Swain(University of Calgary), David Sheridan, Joseph A. Odin(Icahn School of Medicine at Mount Sinai), Carmen Stanca, Stephen A. Harrison(Louisiana State University), Yu Li(Boston University), Mónika Varga(CymaBay Therapeutics (United States)), David Jones(University of Padua), Brian B. Borg(National Institute of Diabetes and Digestive and Kidney Diseases), David Bernstein, Guy Neff, Bruce R. Bacon(Saint Louis University), Michael Galambos, Ke Yang(Chinese Academy of Sciences), Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Douglas Thorburn(Royal Free London NHS Foundation Trust)
Cited by 1
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k